Abbott Laboratories may see boost from St. Jude’s acquisition: Barron’s

Feb 12, 2017 | Bad Credit Loans, Bank Lending, Business Lending, Business Loans, Capital, Economics, Finance, Non-Bank Loans, Working Capital

NEW YORK (Reuters) – Abbott Laboratories is likely to see its shares rise again after trading range-bound for nearly a year on the back of its $25 billion acquisition of medical device-maker St. Jude Medical, Barron’s said on Sunday.